US Pharma MarketingBeeline adds $126M to Bain-backed immunology pipeline from Bristol Myers
Bain Capital, the Canada Pension Plan Investment Board, and Bristol Myers are doubling down on Beeline Medicines with a $126.3 million extension to the original $300 million raise. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act…
embargo lifts June 30 at 7 am ET
Bristol Myers Squibb spinout Beeline Medicines is getting extra love from its existing backers and some of its management team.
Bain Capital, the Canada Pension Plan Investment ...
Source: Endpoints News